Gallium (68GA) rofapitide tetraxetan clinical trials
How each study uses gallium (68GA) rofapitide tetraxetan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the gallium (68GA) rofapitide tetraxetan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
Thomas Hope (2) · Odense University Hospital (1) · Yi Tian (1)
Often tested with
Tested in the same studies.
Copper Cu 64 Rofapitide Tetraxetan (1)
Related medicines
As reviewed, each with the page that says it.
- One of Radiopharmaceuticals source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test gallium (68GA) rofapitide tetraxetan.
- Dec 2026Imaging of Solid Tumors Using FAP-2286Phase 1 · Thomas Hope
- Jul 2027Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.Phase 1 · Yi Tian
Studies
Open first, then newest update. How each study uses gallium (68GA) rofapitide tetraxetan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Imaging of Solid Tumors Using FAP-2286RecruitingPhase 1Thomas HopeNCT04621435Written as Gallium-68 labelled (68Ga-) FAP-2286How we know
- FAP PET/CT for Staging Patients With Breast CancerNot yet recruitingPhase 2Odense University HospitalNCT07523607Written as 68Ga-FAP-2286How we know
- Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.RecruitingPhase 1Yi TianNCT07144085Written as Gallium-68 labelled (68Ga-) FAP-2286How we know
- Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286CompletedPhase 1Thomas HopeNCT05180162Written as 68Ga-FAP-2286How we know
Given beside what is tested · 1 — gallium (68GA) rofapitide tetraxetan is usual care or a partner of the new treatment
Codes
What other systems call gallium (68GA) rofapitide tetraxetan · ClinicalTrials.gg INT018173
- UNII (FDA) UX1FR00T7YGALLIUM (68GA) ROFAPITIDE TETRAXETANOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UX1FR00T7Y | GALLIUM (68GA) ROFAPITIDE TETRAXETAN | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.